Earnings — page 17
Zentalis Completes DENALI Enrollment, Pushes Readout to 2027
Cash, cash equivalents and marketable securities stood at $174.6 million as of June 30, 2026, which the company said funds operations into late 2027.
Whitehawk Extends Cash Runway Into Second Half of 2028
Cash, cash equivalents and short-term investments reached $190.0 million after an $87.5 million May private placement, and the company said that balance is anticipated to fund operations into 2H 2028.
Warner Bros. Discovery Profit Craters Ahead of Paramount Deal
Warner Bros. Discovery (WBD) reported net income tumbled 91% to $149 million as Studios weakness deepened even while streaming carried the quarter.
Voyager’s Alzheimer’s Gene Therapy Cleared For Human Testing
Voyager ended June with $148.8 million in liquid resources and said it expects two Alzheimer’s development milestones in the fourth quarter.
TechTarget Reverses First-Quarter Growth and Restates 2026 Targets
Second-quarter revenue was $116.1 million, down 3.2% from a year earlier, after a 2.1% year-over-year increase in the first quarter.
Targa Posts Record EBITDA as Fee-Based Growth Accelerates
Second-quarter adjusted EBITDA reached $1.603 billion, up 14% sequentially.
TriSalus Restores Sequential Revenue After Expansion Dip
TriNav sales reached $11.4 million in the second quarter as the company kept 2026 guidance at $54 million to $57 million.
Molson Coors Volume Slide Deepens as Costs Escalate
Molson Coors Beverage (TAP-A) reported second-quarter net sales fell 3.3% to $3.10 billion as volume declined 5.4% and mark-to-market commodity losses cut into profit.
Silvaco Posts First Non-GAAP Operating Profit in Two Years
Second-quarter revenue of $17.8 million rose 48% after 26% growth in the first quarter, and non-GAAP operating income reached $0.6 million.
SIGA Completes 19C Stockpile Deliveries After Quiet Quarters
The smallpox-drug maker booked $41.0 million of revenue and $12.5 million of net income in the three months ended June 30, 2026, after two consecutive quarters of losses.
Runway Growth Restores Net Investment Income After SWK Close
Net investment income was $18.2 million, or $0.43 a share, as the specialty finance company closed the SWK Holdings deal and lifted the portfolio to $1.2 billion.
Cartesian Extends Cash Runway Into 2028 After K2HV Loan
Cash, cash equivalents and restricted cash stood at $149.3 million after a $50 million K2 HealthVentures term loan and $19.3 million of year-to-date ATM proceeds.
BRC Group's Core Operating Profit Reaches Highest Since Late 2023
Operating Adjusted EBITDA was $66.0 million in the second quarter as net income available to common shareholders was $18.5 million.
AVITA Medical Raises 2026 Guidance After Record Quarter
Second-quarter revenue hit a record $21.7 million, up 18% from a year earlier, and the company lifted its full-year range to $86 million to $89 million.
Ready Capital’s Distributable Loss Narrowed After First-Quarter Widening
Ready Capital reported a distributable loss of $0.47 a share for the June quarter while keeping its focus on fourth-quarter debt maturities.
CPI Card Group Lifts 2026 Revenue and Cash-Flow Outlook
Second-quarter revenue rose 15% to $149.2 million as the company raised 2026 free-cash-flow guidance to $45 million–$50 million.
Palladyne AI Reiterates 2026 Guidance After Record Quarter
Second-quarter revenue reached $5.8 million, and the company kept its $24 million to $27 million full-year outlook intact.
Montauk's Second-Quarter Revenue Growth Accelerates
Revenue reached $54.0 million, up 19.7% from a year earlier, as Adjusted EBITDA rose 144.5% to $12.3 million.
Lee Raises Fiscal 2026 Ebitda Outlook After Profit Return
The company now expects 22% to 28% year-over-year Adjusted EBITDA growth, after a $5 million net income in the quarter ended June 28, 2026.
Lifetime Brands Raises 2026 Earnings Outlook After Tariff Refunds
The home-products marketer booked a $40.1 million tariff refund, swung to $19.6 million of net income, or $0.87 a share, and lifted full-year profit guidance.
Lineage Chose Animal Testing for New Corneal Cell Therapy
The biotechnology developer reported $4.8 million in quarterly research spending as its new COR1 eye-disease program cleared internal criteria for further preclinical work.
Kenvue Sales Rise as Volume Growth Returns
Adjusted earnings rose 7% to $0.31 a share despite pressure from tariffs and inflation.
Korro Bio Adds Drug Candidate for Genetic Liver and Lung Disease
The RNA-editing drug developer ended June with $137.9 million in cash and securities, which it expects to fund operations into the second half of 2028.
Keurig Dr Pepper Profit Rebounded After JDE Peet’s Acquisition
Net sales reached $7.31 billion after the April acquisition transformed the beverage maker’s business.
Howmet Raises Outlook as Aerospace Demand Accelerates
Second-quarter revenue reached $2.547 billion, topping the high end of Howmet’s prior guidance by $137 million.
Friedman Posts Record Volume and Lifts Earnings
Net earnings reached $12.8 million, or $1.79 a share, on sales of $240.0 million as volume hit about 206,000 tons.
Expensify Lifts Full-Year Free Cash Flow Outlook
The company now estimates $12.0 million to $14.0 million of free cash flow for the year ending December 31, 2026, after a $6.4 million second-quarter print.
Precision BioSciences Reports First Biopsy Proof of cccDNA Elimination
Liver biopsies in ELIMINATE-B showed a 1-log cccDNA drop with under 1% remaining after two PBGENE-HBV doses, and cash stood at $112.4 million at June 30.
Cerence Authorizes First Share Repurchase Program
The board approved up to $30 million of buybacks as third-quarter revenue reached $69.6 million and Adjusted EBITDA rose 50% to $13.5 million.
Corbus Wins FDA Clearance for CRB-701 Phase 3 Trial
Cash of $117.9 million is expected to fund operations into 2028 as the company prepares two September clinical milestones.
Commerce.com's Revenue Growth Stalls After First-Quarter Rebound
Second-quarter revenue was $84.5 million, up 0.1% from a year earlier, after 5% growth in the first quarter, as subscription solutions turned negative.
Citizens Swings to a Loss as Endowment Maturities Recede
Direct insurance premiums reached $48.1 million in the second quarter, the fifteenth straight year-over-year gain in first-year premium.
Blend Labs Growth Cools After a Faster First Quarter
Second-quarter revenue was $33.8 million, up 7% from a year earlier, as non-GAAP operating income reached $7.0 million.
Becton Dickinson Raises Profit Outlook as Revenue Grows
Adjusted earnings from continuing operations increased to $3.23 a share.
Artiva Wins RMAT for AlloNK in Refractory Rheumatoid Arthritis
Cash, cash equivalents and investments stood at $349.4 million as of June 30, 2026, after an approximately $300 million May offering the company said will fund operations into 2029.
ALX Oncology Cash Reaches $153.4 Million After Refinancing
The clinical-stage biotech said cash, cash equivalents and investments of $153.4 million as of June 30, 2026, are sufficient to fund planned operations through the first half of 2028.
Alta Equipment Tightens 2026 Adjusted EBITDA Range
The equipment dealer now expects full-year Adjusted EBITDA of $167.5 million to $177.5 million after second-quarter Adjusted EBITDA of $48.6 million.
Xperi Keeps 2026 Outlook After Advertising Growth
Advertising and related revenue reached $14.98 million in the second quarter, up 54% from a year earlier, as TiVo One monthly active users hit 6.3 million.
Weight Watchers Restores Profit After Peak-Season Marketing Reset
Second-quarter revenue was $162.3 million as Clinical Subscription Revenue reached $39.9 million and Adjusted EBITDA swung to $39.8 million.
TeraWulf's HPC Pivot Accelerates as Anthropic Signs $19 Billion Lease
TeraWulf reported second-quarter revenue of $44.8 million as HPC leasing grew to 71% of the mix and Anthropic signed a 20-year lease worth roughly $19 billion at its Justified Data Campus.
Vanda Reiterates 2026 Revenue Guidance After Fanapt Sales
Second-quarter total net product sales were $50.5 million, excluding about $7.0 million of HETLIOZ orders to be booked in the third quarter.
Entrada Completes ELEVATE-45 Cohort 1 and Starts 10 mg/kg Dosing
Cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, and the company said the balance will fund operations into the third quarter of 2027.
TriplePoint Venture Growth Restarts Supplemental Distributions
The board declared a $0.23 regular payout plus $0.12 of supplemental distributions after a $12.8 million Revolut sale lifted net assets to $0.26 a share.
TaskUs Raises Full-Year Revenue Floor After Guidance Beat
Second-quarter service revenue of $308.9 million topped the high end of the company’s outlook by $10.9 million, prompting a $10 million lift to the 2026 revenue floor.
Stoneridge Reaffirms 2026 Outlook After Record Adjusted Ebitda
Adjusted EBITDA was $5.5 million, or 3.0% of sales, versus $0.8 million a year earlier, as the company kept its $645 million to $670 million revenue range.
SmartRent Restores Core Revenue Growth After a Flat First Quarter
Core revenue reached $38.4 million, up 14% from a year earlier, and Adjusted EBITDA was $0.7 million as the company posted a third straight quarter of positive Adjusted EBITDA.
Seaport Entertainment Posts First Adjusted Profit in Two Years
Non-GAAP adjusted net income attributable to common stockholders was $0.32 million, or $0.02 a share, after a $17.88 million adjusted loss in the first quarter.
RGC Resources' Summer Margin Gain Is Wiped Out by Costs
Operating margin rose $757,000 year over year in the June quarter, but expenses rose by a similar amount and diluted earnings stayed at $0.05 a share.
Portillo's Cuts Corporate Workforce After Same-Sales Slide
Same-restaurant sales fell 1.2% in the second quarter as transactions dropped 3.4% and commodity prices rose 7.0%.
Palmer Square Narrows Mark Losses After a Heavy First Quarter
Net investment income was $12.0 million, or $0.39 a share, as the company declared a $0.36 third-quarter base dividend.